| 吴志勇 吴倩 孙德聪 王治宽 石燕 戴广海.贝伐珠单抗的疗效预测研究现状[J].,2014,14(23):4570-4573 |
| 贝伐珠单抗的疗效预测研究现状 |
| Progress in Response Prediction for Bevacizumab in Anti-tumor Therapy |
| |
| DOI： |
| 中文关键词: 贝伐珠单抗 肿瘤 治疗 疗效预测 |
| 英文关键词: Bevacizumab Neoplasms Therapy Response prediction |
| 基金项目:吴阶平基金项目（320.6750.12401）；国家自然科学基金项目（81372286） |
|
| 摘要点击次数: 589 |
| 全文下载次数: 1080 |
| 中文摘要: |
| 抗血管生成的贝伐珠单抗已被广泛应用于多种恶性肿瘤的治疗。但因其受益人群有限及逐渐出现的获得性耐药，也限制了
其对患者总生存的改善。迫切需要寻找有效的预测贝伐珠单抗疗效的预测因子指导临床应用。人们在生物标记物、影像学方面进
行了大量探索，但目前尚没有一个公认的普遍适用的临床预测指标，仍需要从多角度出发，进行进一步的基础研究及临床研究去
发现和验证有效的疗效预测指标。 |
| 英文摘要: |
| Bevacizumab has been widely used in the treatment of a variety of neoplasms. However, some patients do not respond
or gradually develop resistance, resulting in rather modest gains in terms of overall survival. It is urgent to find surrogate marker that can
guide selection of patients for whom bevacizumab therapy is most beneficial. Although a large number of exploration has been done in
biomarkers and imaging, there is no one recognized universally applicable clinical predictors yet. Thus more basic researches and clinical
trials should be performed to find out effective surrogate markers in bevacizumab's therapy. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
